| B淋巴细胞表面分子靶向治疗类风湿关节炎的研究进展 |
| |
| 作者姓名： | Di W Chang Y Wu YJ Wei W |
| |
| 作者单位： | 安徽医科大学临床药理研究所,抗炎免疫药理学省部共建教育部重点实验室,合肥,230032 |
| |
| 基金项目： | 国家自然科学基金(30973543)资助课题 |
| |
| 摘 要： | 类风湿关节炎(rheumatoid arthritis,RA)是一种慢性、系统性的自身免疫性疾病,迄今病因尚不明确,且缺乏针对其安全有效的治疗药物.由于B淋巴细胞在RA致病机制中的重要作用,近年来不断有针对B淋巴细胞上不同靶点的治疗药物推出.这些B淋巴细胞靶向生物制剂包括针对CD20分子的抗CD20单克隆抗体,如rituximab、ocrelizumab和ofatumumab等;针对B淋巴细胞刺激因子(B lymphocyte stimulator,BLyS)及其受体的belimumab和atacicept等以及处于初期研究阶段的抗CD22单克隆抗体和B、T淋巴细胞之间CD40/CD40L共刺激反应阻断剂等.上述靶向制剂的疗效在对RA及其动物模型的治疗中得到了证实,提示将B淋巴细胞作为RA治疗靶点是一项非常有前景的治疗策略.
|
| 关 键 词： | B淋巴细胞 类风湿关节炎 B淋巴细胞刺激因子 |
Research progress on B cell surface molecules targeted therapy in rheumatoid arthritis |
| |
| Di W,Chang Y,Wu YJ,Wei W.Research progress on B cell surface molecules targeted therapy in rheumatoid arthritis[J].Progress in Physiological Sciences,2011,42(3):175-180. |
| |
| Authors: | Di Wang Chang Yan Wu Yu-Jing Wei Wei |
| |
| Institution: | WANG Di,CHANG Yan,WU Yu-Jing,WEI Wei(Institute of Clinical Pharmacology,Anhui Medical University,Key Laboratory of Anti-inflammatory and Immunopharmacology of Education Ministry of China,Hefei 230032,China) |
| |
| Abstract: | Rheumatoid arthritis(RA) is a chronic and systemic autoimmune disease,it's pathogenic mechanism is unknown and there is a lack of safe and effective therapeutic drug on RA.Because of important function of B cells in RA pathogenic mechanism,many therapeutic drugs targeted on different positions of B cells are emerging in RA therapy.These B cell-targeted therapeutic biologic agents include anti-CD20 monoclonal antibody(such as rituximab,ocrelizumab and ofatumumab),biologic agents which targeted B lymphocyte s... |
| |
| Keywords: | CD20 |
| 本文献已被 CNKI 万方数据 PubMed 等数据库收录！ |
|
